Cloud-clone
SKU:MAB367Hu21
Monoclonal Antibody to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
Monoclonal Antibody to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
Couldn't load pickup availability
Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
Product No.
MAB367Hu21
Organism Species
Homo sapiens (Human).
Source
Monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
2-2#
Ig Isotype
IgG2b Kappa
Purification
Protein A + Protein G affinity chromatography
Label
None
Immunogen
RPB367Hu01-Recombinant Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
1mg/mL
Organism Species More
Mus musculus (Mouse), Rattus norvegicus (Rat)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against VEGFR2. It has been selected for its ability to recognize VEGFR2 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| APMIS | Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway PubMed: 23398358 |
| Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study PubMed: 26689470 |
| Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study Pubmed:26689470 |
| Journal of Cellular Physiology | A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells. pubmed:27925188 |
| Regenerative Biomaterials | The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic 10.1093/rb/rbx028 |
| International Journal of Immunopathology and Pharmacology | VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these … Pubmed:29985074 |
| JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris Pubmed: 32043381 |
| Journal of Genetic Engineering and Biotechnology | Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells 33523322 |
| Mol Cell Biochem | Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy 34324118 |
| BMC Nephrol | Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys Pubmed:35643467 |
Share
